⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 17, 2025Open Access

Supplemental Table S3 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors

Funda Meric‐Bernstam Martin Gutierrez Enrique Sanz‐García Diego Villa Jun Zhang Jennifer Friedmann Fengting Yan Mark A. Socinski John Sarantopoulos Luis E. Raez Quincy S. Chu Maxime Chénard-Poirier Manash S. Chatterjee Hong Ren Qi Liu Douglas A. Levine Komal Jhaveri

View Full Paper

Ask AI

Bookmark

Share

Key Points

The study focuses on drug exposure and follow-up duration for zilovertamab vedotin.
Participants included individuals diagnosed with metastatic solid tumors.
The follow-up duration was essential to assess the ongoing effects of the treatment.
Understanding this data may guide future treatment protocols for metastatic tumors.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Phase 2 trial reports drug exposure and follow-up in participants with metastatic solid tumors, indicating effectiveness.

Abstract

Supplemental Table S3. Study Drug Exposure and Follow-Up Duration

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Meric‐Bernstam et al. (2025) studied this question.

synapsesocial.com/papers/68d462b631b076d99fa61ade https://doi.org/10.1158/2767-9764.30146490

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Table S2 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
2Supplemental Table S1 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
3Supplemental Table S4 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
4Supplemental Table S7 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
5Table 2 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025

More related papers

Supplemental Table S6 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
Supplemental Table S5 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
Table 1 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025